SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

Schall, Brown & Schwartz LLP reminded SPRY investors of a securities fraud class action alleging misleading statements about the insurance coverage timeline for neffy. The complaint claims ARS knew or disregarded the risk that CVS Caremark's formulary addition of neffy could shift coverage timelines and impact commercialization.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.